148 related articles for article (PubMed ID: 25651421)
1. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.
Yang ZZ; Liang AB; Ansell SM
Leuk Lymphoma; 2015; 56(9):2498-504. PubMed ID: 25651421
[TBL] [Abstract][Full Text] [Related]
2. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover.
Krejsgaard T; Lindahl LM; Mongan NP; Wasik MA; Litvinov IV; Iversen L; Langhoff E; Woetmann A; Odum N
Semin Immunopathol; 2017 Apr; 39(3):269-282. PubMed ID: 27717961
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond.
Ansell SM
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):618-621. PubMed ID: 29222312
[TBL] [Abstract][Full Text] [Related]
4. Insulin Receptor-Mediated Stimulation Boosts T Cell Immunity during Inflammation and Infection.
Tsai S; Clemente-Casares X; Zhou AC; Lei H; Ahn JJ; Chan YT; Choi O; Luck H; Woo M; Dunn SE; Engleman EG; Watts TH; Winer S; Winer DA
Cell Metab; 2018 Dec; 28(6):922-934.e4. PubMed ID: 30174303
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
6. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity.
Joffre O; Nolte MA; Spörri R; Reis e Sousa C
Immunol Rev; 2009 Jan; 227(1):234-47. PubMed ID: 19120488
[TBL] [Abstract][Full Text] [Related]
8. Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics.
Donnou S; Galand C; Daussy C; Crozet L; Fridman WH; Sautès-Fridman C; Fisson S
Clin Exp Immunol; 2011 Sep; 165(3):329-37. PubMed ID: 21668435
[TBL] [Abstract][Full Text] [Related]
9. Role of the microenvironment across histological subtypes of NHL.
Tarte K
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):610-617. PubMed ID: 29222311
[TBL] [Abstract][Full Text] [Related]
10. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions.
Dutt S; Atallah MB; Minamida Y; Filatenkov A; Jensen KP; Iliopoulou BP; Tamosiuniene R; Waters J; Engleman EG; Strober S
Blood Adv; 2018 Oct; 2(19):2568-2580. PubMed ID: 30301812
[TBL] [Abstract][Full Text] [Related]
11. The Role of Inflammatory Cytokines in Creating T Cell Exhaustion in Cancer.
Sabzevary-Ghahfarokhi M; Shirzad H; Rafieian-Kopaei M; Ghatreh-Samani M; Shohan M
Cancer Biother Radiopharm; 2018 Sep; 33(7):267-273. PubMed ID: 30004799
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
13. Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma.
Yang ZZ; Grote DM; Ziesmer SC; Xiu B; Yates NR; Secreto FJ; Hodge LS; Witzig TE; Novak AJ; Ansell SM
PLoS One; 2013; 8(3):e59456. PubMed ID: 23555036
[TBL] [Abstract][Full Text] [Related]
14. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
15. The challenge of the microenvironment in B-cell lymphomas.
Coupland SE
Histopathology; 2011 Jan; 58(1):69-80. PubMed ID: 21261684
[TBL] [Abstract][Full Text] [Related]
16. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.
Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R
Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649
[TBL] [Abstract][Full Text] [Related]
17. TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.
Yang ZZ; Grote DM; Xiu B; Ziesmer SC; Price-Troska TL; Hodge LS; Yates DM; Novak AJ; Ansell SM
Leukemia; 2014 Sep; 28(9):1872-84. PubMed ID: 24569779
[TBL] [Abstract][Full Text] [Related]
18. Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?
Schultze JL
Leuk Lymphoma; 1999 Jan; 32(3-4):223-36. PubMed ID: 10037020
[TBL] [Abstract][Full Text] [Related]
19. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Josefsson SE; Beiske K; Blaker YN; Førsund MS; Holte H; Østenstad B; Kimby E; Köksal H; Wälchli S; Bai B; Smeland EB; Levy R; Kolstad A; Huse K; Myklebust JH
Cancer Immunol Res; 2019 Mar; 7(3):355-362. PubMed ID: 30659053
[TBL] [Abstract][Full Text] [Related]
20. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma.
Sicard H; Al Saati T; Delsol G; Fournié JJ
Mol Med; 2001 Oct; 7(10):711-22. PubMed ID: 11713370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
